|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-4.92/-2.71
|
企业价值
800.61M
|
资产负债 |
每股账面净值
-0.12
|
现金流量 |
现金流量率
--
|
损益表 |
收益
27.12M
|
每股收益
2.07
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比较之报价最少15分钟延迟
业务概览
|
|||
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |